1-10 of 10
Alessandra Cesano, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Mark D. Minden, MD PhD, Tressa Hood, MSc, Sarah E. Church, PhD, Stephen Reeder, BSc, Heidi Altmann, PhD, Amy H Sullivan, BSc, Elena J Viboch, MSc, Tasleema Patel, Narmin Ibrahimova, Sarah E. Warren, PhD, Andrea Arruda, Marc Schmitz, MD, Yan Liang, PhD, Alessandra Cesano, MD PhD, A. Graham Pockley, PhD, Peter Valk, PhD, Bob Löwenberg, MD PhD, Martin Bornhäuser, MD, Sarah K. Tasian, MD, Michael P. Rettig, PhD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD, Sergio Rutella, MDPhDFRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 460.
https://doi.org/10.1182/blood-2019-121870
Published: 2019
Journal Articles

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Sergio Rutella, MD PhD FRCPath, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Elena Viboch, MSc, Amy H Sullivan, BSc, Tressa Hood, MSc, Sarah E. Warren, PhD, Alessandra Cesano, MD PhD, Ross La Motte-Mohs, PhD, John Muth, MS, Helene Lelièvre, PhD PharmD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 444.
https://doi.org/10.1182/blood-2018-99-111539
Published: 2018
Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Norbert Vey, MD PhD, John Godwin, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, Gerwin Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra L. Sweet, MD, Farhad Ravandi, MD, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD PhD FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La Motte-Mohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Lowenberg, MD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 764.
https://doi.org/10.1182/blood-2018-99-117085
Published: 2018
Journal Articles

Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy.

Steven Kornblau, M.D., M. D. Minden, MD, PhD, David B. Rosen, PhD, Santosh Putta, PhD, Aileen C. Cohen, MD, PhD, Todd Covey, Wendy J. Fantl, PhD, Urte Gayko, PhD, Alessandra Cesano, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1582.
https://doi.org/10.1182/blood.V114.22.1582.1582
Published: 2009
Journal Articles

Single Cell Profiling of B Cell Receptor Signaling and Apoptosis Networks in Chronic Lymphocytic Leukemia: Association with in Vitro Sensitivity to Fludarabine Monophosphate (F-ara-A).

Erik Evensen, PhD, Adam Palazzo, Ying-Wen Huang, MS, Alessandra Cesano, MD, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD, Wendy J. Fantl, PhD
Journal: Blood
Blood (2009) 114 (22): 1263.
https://doi.org/10.1182/blood.V114.22.1263.1263
Published: 2009
Journal Articles

FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.

M. D. Minden, MD, PhD, Steven M. Kornblau, MD, David B. Rosen, PhD, Aileen Cleary Cohen, MD, PhD, Urte Gayko, PhD, Santosh Putta, PhD, John Woronicz, PhD, Wendy J. Fantl, PhD, Alessandra Cesano, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1588.
https://doi.org/10.1182/blood.V114.22.1588.1588
Published: 2009
Journal Articles

Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in Acute Myeloid Leukemia.

David B. Rosen, PhD, James A Cordeiro, David M. Soper, PhD, Ying-Wen Huang, MS, Donna E. Hogge, MD, PhD, Roland B. Walter, MD, PhD, Alessandra Cesano, MD, PhD, Wendy J. Fantl, PhD
Journal: Blood
Blood (2009) 114 (22): 2745.
https://doi.org/10.1182/blood.V114.22.2745.2745
Published: 2009
Journal Articles

Classification of Acute Myeloid Leukemia (AML) Based On Apoptosis and Myeloid Signaling Networks.

David B. Rosen, PhD, M. D. Minden, MD, PhD, Santosh Putta, PhD, Todd Covey, Ying W. Huang, MSc, Alessandra Cesano, MD, PhD, Wendy J. Fantl, PhD
Journal: Blood
Blood (2009) 114 (22): 325.
https://doi.org/10.1182/blood.V114.22.325.325
Published: 2009
Journal Articles

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

David M. Soper, PhD, Ying-Wen Huang, MS, Francois Wilhelm, MD, Ph.D, S. C. Cosenza, E. Premkumar Reddy, PhD, Alessandra Cesano, MD, PhD, Peter L Greenberg, MD, Wendy J. Fantl, PhD
Journal: Blood
Blood (2009) 114 (22): 3827.
https://doi.org/10.1182/blood.V114.22.3827.3827
Published: 2009
Journal Articles

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

Alessandra Cesano, MD, PhD, John Woronicz, PhD, Aileen Cleary Cohen, MD, PhD, Todd Covey, Santosh Putta, PhD, Urte Gayko, PhD, Wendy J. Fantl, PhD, S.M. Kornblau, M.D.
Journal: Blood
Blood (2009) 114 (22): 397.
https://doi.org/10.1182/blood.V114.22.397.397
Published: 2009